Celecoxib in breast cancer prevention and therapy

References

• EvansDGHowellABreast cancer risk-assessment modelsBr Cancer Res200795 213
   PubMed Web of Science ®Google Scholar
• SiegelRLMillerKDJemalACancer statistics, 2018CA Cancer J Clin 20182018681 73029313949
   PubMed Web of Science ®Google Scholar
• RayburnEEzellSJZhangRAnti-Inflammatory Agents for Cancer TherapyMol Cell Pharmacol200911 294320333321
   PubMedGoogle Scholar
• CoussensLMWerbZInflammation and cancerNature20024206917 86086712490959
   PubMed Web of Science ®Google Scholar
• AllenMDJonesLJThe role of inflammation in progression of breast cancer: Friend or foe? (Review)Int J Oncol2015473 79780526165857
   PubMed Web of Science ®Google Scholar
• ChanDSBanderaEVGreenwoodDCNoratTCirculating C-Reactive Protein and Breast Cancer Risk-Systematic Literature Review and Meta-analysis of Prospective Cohort StudiesCancer Epidemiol Biomarkers Prev20152410 1439144926224798
   PubMed Web of Science ®Google Scholar
• LandskronGde La FuenteMThuwajitPThuwajitCHermosoMAChronic inflammation and cytokines in the tumor microenvironmentJ Immunol Res201420142 1491851924901008
   PubMed Web of Science ®Google Scholar
• GallieraECorsiMBonecchiRLocatiMMantovaniAChemokines as pharmacological targetsMini Rev Med Chem200887 63864618537719
   PubMed Web of Science ®Google Scholar
• KnowlesMANovel therapeutic targets in bladder cancer: mutation and expression of FGF receptorsFuture Oncol200841 718318241002
   PubMed Web of Science ®Google Scholar
• BoscoJLPalmerJRBoggsDAHatchEERosenbergLRegular aspirin use and breast cancer risk in US Black womenCancer Causes Control20112211 1553156121877122
   PubMed Web of Science ®Google Scholar
• Díaz-CruzESShapiroCLBrueggemeierRWCyclooxygenase Inhibitors Suppress Aromatase Expression and Activity in Breast Cancer CellsJ Clin Endocrinol Metab2005905 2563257015687328
   PubMed Web of Science ®Google Scholar
• MasferrerJLKokiASeibertKCOX-2 inhibitors. A new class of antiangiogenic agentsAnn N Y Acad Sci19998891 CANCER PREVEN 848610668485
   PubMedGoogle Scholar
• BennettABerstockDACarrollMAStamfordIFWilsonAJBreast cancer, its recurrence, and patient survival in relation to tumor prostaglandinsAdv Prostaglandin Thromboxane Leukot Res1983122993026221606
   PubMedGoogle Scholar
• LalaPKAl-MutterNOrucevicAEffects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ miceInt J Cancer1997733 3713809359485
   PubMed Web of Science ®Google Scholar
• TimoshenkoAVXuGChakrabartiSLalaPKChakrabortyCRole of prostaglandin E2 receptors in migration of murine and human breast cancer cellsExp Cell Res20032892 26527414499627
   PubMed Web of Science ®Google Scholar
• MajumderMXinXLiuLGirishGVLalaPKProstaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functionsCancer Sci20141059 1142115124981602
   PubMed Web of Science ®Google Scholar
• ChangS-HLiuCHConwayRRole of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progressionProc Natl Acad Sci U S A20041012 59159614688410
   PubMed Web of Science ®Google Scholar
• BhattacharjeeRNTimoshenkoAVCaiJLalaPKRelationship between cyclooxygenase-2 and human epidermal growth factor receptor 2 in vascular endothelial growth factor C up-regulation and lymphangiogenesis in human breast cancerCancer Sci20101019 2026203220608938
   PubMed Web of Science ®Google Scholar
• KuneGAKuneSWatsonLFColorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer StudyCancer Res19884815 439944043390835
   PubMed Web of Science ®Google Scholar
• KangHFWangXJLiuXXDaiZJXueFJXueXHChemopreventive effect of celecoxib against DMBA-induced breast cancer and its mechanismNan Fang Yi Ke Da Xue Xue Bao20062611 1599160217121709
   PubMedGoogle Scholar
• WoditschkaSHaagJDMauBLubetRAGouldMNChemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neuinduced retroviral rat modelBreast Cancer Res2008101 R1818279516
   PubMed Web of Science ®Google Scholar
• Lanza-JacobySMillerSFlynnJThe cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu miceCancer Epidemiol Biomarkers Prev20031212 1486149114693742
   PubMed Web of Science ®Google Scholar
• LiuYKosakaAIkeuraMPremetastatic soil and prevention of breast cancer brain metastasisNeuro Oncol2013157 89190323595625
   PubMed Web of Science ®Google Scholar
• HarrisREBeebe-DonkJAlshafieGAReduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitorsBMC Cancer200661 2716445867
   PubMed Web of Science ®Google Scholar
• AshokVDashCRohanTESprafkaJMTerryPDSelective cyclooxygenase-2 (COX-2) inhibitors and breast cancer riskBreast2011201 667020724158
   PubMed Web of Science ®Google Scholar
• DaiZ-JMaX-BKangH-FAntitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in Vitro and in VivoCancer Cell Int2012121 5323249419
   PubMed Web of Science ®Google Scholar
• BoccaCBozzoFBassignanaAMigliettaAAntiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell linesMol Cell Biochem20113501–2 597021140284
   PubMed Web of Science ®Google Scholar
• BrandãoRDVeeckJvan de VijverKKA randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancerBreast Cancer Res2013152 R2923566419
   PubMed Web of Science ®Google Scholar
• BasuGDPathangeyLBTinderTLGendlerSJMukherjeePMechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cellsBreast Cancer Res200574 R42243515987447
   PubMed Web of Science ®Google Scholar
• BasuGDPathangeyLBTinderTLLagioiaMGendlerSJMukherjeePCyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancerMol Cancer Res2004211 63264215561779
   PubMed Web of Science ®Google Scholar
• BarnesNLPWarnbergFFarnieGCyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancerBr J Cancer2007964 57558217285134
   PubMed Web of Science ®Google Scholar
• SinghBIrvingLRTaiKLucciAOverexpression of COX-2 in celecoxib-resistant breast cancer cell linesJ Surg Res20101632 23524320691996
   PubMed Web of Science ®Google Scholar
• BaumannKHKlusmeierEEggemannIEffects of celecoxib and ly117018 combination on human breast cancer cells in vitroBreast Cancer20093233421556247
   PubMedGoogle Scholar
• WangLLiuLHShanBEZhangCSangMXLiJCelecoxib promotes apoptosis of breast cancer cell line MDA-MB-231 through down-regulation of the NF-kappaB pathwayAi Zheng2009286 569574 Chinese19635192
   PubMedGoogle Scholar
• JendrossekVTargeting apoptosis pathways by Celecoxib in cancerCancer Lett20133322 31332421345578
   PubMed Web of Science ®Google Scholar
• LiZHaoQLuoJUSP4 inhibits p53 and NF-κB through deubiquitinating and stabilizing HDAC2Oncogene20163522 2902291226411366
   PubMed Web of Science ®Google Scholar
• TuynmanJBVermeulenLBoonEMCyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancerCancer Res2008684 1213122018281498
   PubMed Web of Science ®Google Scholar
• XiaJ-JPeiL-BZhuangJ-PCelecoxib Inhibits β-Catenin-Dependent Survival of the Human Osteosarcoma MG-63 Cell LineJ Int Med Res2010384 1294130420926002
   PubMed Web of Science ®Google Scholar
• Takahashi-YanagaFKahnMTargeting Wnt signaling: can we safely eradicate cancer stem cells?Clin Cancer Res20101612 3153316220530697
   PubMed Web of Science ®Google Scholar
• FoddeRBrabletzTWnt/β-catenin signaling in cancer stemness and malignant behaviorCurr Opin Cell Biol2007192 15015817306971
   PubMed Web of Science ®Google Scholar
• MaierTJJanssenASchmidtRGeisslingerGGröschSTargeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cellsFASEB J20051910 1353135515946992
   PubMed Web of Science ®Google Scholar
• AltieriDCNew wirings in the survivin networksOncogene20082748 6276628418931693
   PubMed Web of Science ®Google Scholar
• KimY-YLeeE-JKimY-KAnti-cancer effects of celecoxib in head and neck carcinomaMol Cells2010292 18519420082220
   PubMed Web of Science ®Google Scholar
• KardoshASorianoNPyrkoPReduced survivin expression and tumor cell survival during chronic hypoxia and further cytotoxic enhancement by the cyclooxygenase-2 inhibitor celecoxibJ Biomed Sci2007145 64766217440835
   PubMed Web of Science ®Google Scholar
• HsiaoP-WChangC-CLiuH-FTsaiC-MChiuTHChaoJ-IActivation of p38 mitogen-activated protein kinase by celecoxib oppositely regulates survivin and gamma-H2AX in human colorectal cancer cellsToxicol Appl Pharmacol20072221 9710417540426
   PubMed Web of Science ®Google Scholar
• FukadaKTakahashi-YanagaFSakoguchi-OkadaNCelecoxib induces apoptosis by inhibiting the expression of survivin in HeLa cellsBiochem Biophys Res Commun20073574 1166117117466271
   PubMed Web of Science ®Google Scholar
• Sakoguchi-OkadaNTakahashi-YanagaFFukadaKCelecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cellsBiochem Pharmacol2007739 1318132917270149
   PubMed Web of Science ®Google Scholar
• BaiX-MJiangHDingJ-XProstaglandin E2 upregulates survivin expression via the EP1 receptor in hepatocellular carcinoma cellsLife Sci2010865–6 21422320035770
   PubMed Web of Science ®Google Scholar
• ZhaoSCaiJBianHGuiLZhaoFSynergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatinCancer Invest2009276 63664019387877
   PubMed Web of Science ®Google Scholar
• GaiserTBeckerMRHabelATRAIL-mediated apoptosis in malignant glioma cells is augmented by celecoxib through proteasomal degradation of survivinNeurosci Lett20084422 10911318634847
   PubMed Web of Science ®Google Scholar
• Tran-ThanhDButtarsSWenYWilsonCDoneSJCyclooxygenase-2 inhibition for the prophylaxis and treatment of preinvasive breast cancer in a her-2/neu mouse modelCancer Prev Res201032 202211
   PubMed Web of Science ®Google Scholar
• LangersIRenouxVMThiryMDelvennePJacobsNNatural killer cells: role in local tumor growth and metastasisBiologics20126738222532775
   PubMedGoogle Scholar
• HoweLSubbaramaiahKBrownAMDannenbergAJCyclooxygenase-2: a target for the prevention and treatment of breast cancerEndocr Relat Cancer200182 9711411397667
   PubMed Web of Science ®Google Scholar
• MarkosyanNChenEPEvansRANdongVVonderheideRHSmythEMMammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activityBreast Cancer Res2013155 R7524004819
   PubMed Web of Science ®Google Scholar
• KunduNWalserTCMaXFultonAMCyclooxygenase inhibitors modulate NK activities that control metastatic diseaseCancer Immunol Immunother20055410 98198715891886
   PubMed Web of Science ®Google Scholar
• GallouetA-STravertMBresson-BepoldinLCOX-2-independent effects of celecoxib sensitize lymphoma B cells to TRAIL-mediated apoptosisClin Cancer Res20142010 2663267324637636
   PubMed Web of Science ®Google Scholar
• LangSPicuAHofmannTCOX-inhibitors relieve the immunosuppressive effect of tumor cells and improve functions of immune effectorsInt J Immunopathol Pharmacol2006192 40941916831307
   PubMed Web of Science ®Google Scholar
• FerrandinaGCelecoxib Up-Regulates the Expression of the Chain of T Cell Receptor Complex in Tumor-Infiltrating Lymphocytes in Human Cervical CancerClin Cancer Res2006127 2055206016609015
   PubMed Web of Science ®Google Scholar
• SarkarDFisherPBMolecular mechanisms of aging-associated inflammationCancer Lett20062361 132315978720
   PubMed Web of Science ®Google Scholar
• JoyceJAPollardJWMicroenvironmental regulation of metastasisNat Rev Cancer200994 23925219279573
   PubMed Web of Science ®Google Scholar
• BissellMJHinesWCWhy don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progressionNat Med2011173 32032921383745
   PubMed Web of Science ®Google Scholar
• KimSKimSHHurSMSilibinin prevents TPA-induced MMP-9 expression by down-regulation of COX-2 in human breast cancer cellsJ Ethnopharmacol20091262 25225719715751
   PubMed Web of Science ®Google Scholar
• AfsharimaniBCabotPJParatM-OEffect of lysine antifibrinolytics and cyclooxygenase inhibitors on the proteolytic profile of breast cancer cells interacting with macrophages or endothelial cellsBr J Anaesth2014113Suppl 1 i22i3124418973
   PubMedGoogle Scholar
• JaimesEATianR-XPearseDRaijLUp-regulation of glomerular COX-2 by angiotensin II: Role of reactive oxygen speciesKidney Int2005685 2143215316221213
   PubMed Web of Science ®Google Scholar
• ChangY-WEPutzerKRenLDifferential regulation of cyclo-oxygenase 2 expression by small GTPases Ras, Rac1, and RhoAJ Cell Biochem2005962 31432916088958
   PubMed Web of Science ®Google Scholar
• KaulRVermaSCMurakamiMLanKChoudhuriTRobertsonESEpstein-Barr virus protein can upregulate cyclo-oxygenase-2 expression through association with the suppressor of metastasis Nm23-H1J Virol2006803 1321133116415009
   PubMed Web of Science ®Google Scholar
• Diaz-CruzEBrueggemeierRInterrelationships between cyclo-oxygenases and aromatase: unraveling the relevance of cyclo-oxygenase inhibitors in breast cancerAnticancer Agents Med Chem200663 22123216712450
   PubMedGoogle Scholar
• HarrisRBeebeJAlshafieGAReduction in cancer risk by selective and nonselective cyclooxygenase-2 (COX-2) inhibitorsJ Exp Pharmacol20124919627186121
   PubMedGoogle Scholar
• BrueggemeierRWQuinnALParrettMLJoarderFSHarrisRERobertsonFMCorrelation of aromatase and cyclooxygenase gene expression in human breast cancer specimensCancer Lett19991401–2 273510403538
   PubMed Web of Science ®Google Scholar
• TerryMBGammonMDZhangFAssociation of frequency and duration of aspirin use and hormone receptor status with breast cancer riskJAMA200429120 2433244015161893
   PubMed Web of Science ®Google Scholar
• HolmesMDChenWYLiLHertzmarkESpiegelmanDHankinsonSEAspirin intake and survival after breast cancerJ Clin Oncol2010289 1467147220159825
   PubMed Web of Science ®Google Scholar
• ChanATOginoSFuchsCSAspirin use and survival after diagnosis of colorectal cancerJAMA20093026 64965819671906
   PubMed Web of Science ®Google Scholar
• UrsinGHovanessian-LarsenLPariskyYRPikeMCWuAHAhWGreatly increased occurrence of breast cancers in areas of mammographically dense tissueBreast Cancer Res200575 R60560816168104
   PubMed Web of Science ®Google Scholar
• BoydNFMammographic density and risk of breast cancerAm Soc Clin Oncol Educ Book2013
   PubMedGoogle Scholar
• PetterssonAGraffREUrsinGMammographic density phenotypes and risk of breast cancer: a meta-analysisJ Natl Cancer Inst20141065
   PubMedGoogle Scholar
• EsbonaKInmanDSahaSCOX-2 modulates mammary tumor progression in response to collagen densityBreast Cancer Res2016181 3527000374
   PubMedGoogle Scholar
• LiHYangBHuangJCyclooxygenase-2 in tumor-associated macrophages promotes breast cancer cell survival by triggering a positive-feedback loop between macrophages and cancer cellsOnco-target2015630 2963729650
   Google Scholar
• GuptaGPNguyenDXChiangACMediators of vascular remodelling co-opted for sequential steps in lung metastasisNature20074467137 76577017429393
   PubMed Web of Science ®Google Scholar
• LeahyKKokiAMasferrerJRole of cyclooxygenases in angiogenesisCurr Med Chem2000711 1163117011032965
   PubMed Web of Science ®Google Scholar
• ZhaSYegnasubramanianVNelsonWGIsaacsWBde MarzoAMCyclooxygenases in cancer: progress and perspectiveCancer Lett20042151 12015374627
   PubMed Web of Science ®Google Scholar
• FosslienEReview: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesisAnn Clin Lab Sci2001314 32534811688844
   PubMed Web of Science ®Google Scholar
• ZhangYDaakaYPGE2 promotes angiogenesis through EP4 and PKA C pathwayBlood201111819 5355536421926356
   PubMed Web of Science ®Google Scholar
• BasuGDLiangWSStephanDAA novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cellsBreast Cancer Res200686 R6917156488
   PubMed Web of Science ®Google Scholar
• FifeRSStottBCarrREEffects of a selective cyclooxygenase-2 inhibitor on cancer cells in vitroCancer Biol Ther200432 22823214726667
   PubMed Web of Science ®Google Scholar
• HahnTAlvarezIKobieJJShort-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancerInt J Cancer20061189 2220223116331615
   PubMed Web of Science ®Google Scholar
• SunTWZhWWengXSCelecoxib can suppress expression of genes associated with PGE2 pathway in chondrocytes under inflammatory conditionsInt J Clin Exp Med201587 109021091026379884
   PubMed Web of Science ®Google Scholar
• FournierLSNovikovVLucidiVMR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in ratsRadiology20072431 10511117329684
   PubMed Web of Science ®Google Scholar
• HanFZhangSZhangLHaoQThe overexpression and predictive significance of MMP-12 in esophageal squamous cell carcinomaPathol Res Pract201721312 1519152229033183
   PubMed Web of Science ®Google Scholar
• KumarBNPRajputSDeyKKCelecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signalingBMC Cancer2013131 27323731702
   PubMedGoogle Scholar
• VaishVSanyalSNRole of Sulindac and Celecoxib in the regulation of angiogenesis during the early neoplasm of colon: Exploring PI3-K/PTEN/Akt pathway to the canonical Wnt/β-catenin signalingBiomed Pharmacother2012665 35436722397759
   PubMed Web of Science ®Google Scholar
• KalaliniaFElahianFBehravanJPotential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell linesJ Cancer Res Clin Oncol20111372 32133020422426
   PubMed Web of Science ®Google Scholar
• KalaliniaFElahianFMosaffaFBehravanJCelecoxib Up Regulates the Expression of Drug Efflux Transporter ABCG2 in Breast Cancer Cell LinesIran J Pharm Res2014134 1393140125587329
   PubMed Web of Science ®Google Scholar
• RatnasingheDDaschnerPJAnverMRCyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible?Anticancer Res2001213C 2141214711501838
   PubMed Web of Science ®Google Scholar
• MillerBPatelVASorokinACyclooxygenase-2 rescues rat mesangial cells from apoptosis induced by adriamycin via upregulation of multidrug resistance protein 1 (P-glycoprotein)J Am Soc Nephrol2006174 97798516540558
   PubMed Web of Science ®Google Scholar
• SorokinACyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotypeCurr Pharm Des2004106 64765714965327
   PubMed Web of Science ®Google Scholar
• XiaWZhaoTLvJCelecoxib enhanced the sensitivity of cancer cells to anticancer drugs by inhibition of the expression of P-glycoprotein through a COX-2-Independent MannerJ Cell Biochem20091081 18119419562670
   PubMed Web of Science ®Google Scholar
• ChenCShenHLYangJChenQYXuWLWlXPreventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxibJ Cancer Res Clin Oncol20111371 91720229271
   PubMed Web of Science ®Google Scholar
• HidaTKozakiKItoHSignificant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agentsClin Cancer Res200287 2443244712114451
   PubMed Web of Science ®Google Scholar
• van WijngaardenJvan BeekEvan RossumGCelecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-κB-mediated increase of intracellular doxorubicin accumulationEur J Cancer2007432 43344217097285
   PubMed Web of Science ®Google Scholar
• IrieTTsujiiMTsujiSSynergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-γInt J Cancer20071214 87888317450522
   PubMed Web of Science ®Google Scholar
• YoungSDLafrenieRMClemonsMJPhase ii trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancerCurr Oncol2012192 e758322514500
   PubMed Web of Science ®Google Scholar
• FabiAMetroGPapaldoPImpact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluationCancer Chemother Pharmacol2008624 71772518071704
   PubMed Web of Science ®Google Scholar
• PerroudHAAlasinoCMRicoMJMetastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of responseCancer Chemother Pharmacol2016772 36537426721701
   PubMed Web of Science ®Google Scholar
• ChowLWLooWTWaiCCLuiELZhuLToiMStudy of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patientsBiomed Pharmacother200559Suppl 2 S298S30116507397
   PubMedGoogle Scholar
• ChowLWTungSYNgTYTyNConcurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 studyExpert Opin Investig Drugs2013223 299307
   PubMed Web of Science ®Google Scholar
• ChowLWLooWTYipAYNgELAcceptable cardiac safety profile of neoadjuvant 5-fluorouracil, epirubicin, cyclophosphamide and celecoxib (FEC-C) for breast cancer: a subanalysis of biomarkers for cardiac injuryInt J Biol Markers2013281 3237
   Web of Science ®Google Scholar
• UenoTChowLWToiMIncreases in circulating VEGF levels during COX-2 inhibitor treatment in breast cancer patientsBiomed Pharmacother2006606 27727916806797
   PubMed Web of Science ®Google Scholar
• LimJSParkYLeeBMKimHSYoonSCo-treatment with Celecoxib or NS398 Strongly Sensitizes Resistant Cancer Cells to Antimitotic Drugs Independent of P-gp InhibitionAnticancer Res20163610 5063507027798865
   PubMed Web of Science ®Google Scholar
• WebbTCarterJRobertsJLCelecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistanceCancer Biol Ther20151611 1660167026417912
   PubMed Web of Science ®Google Scholar
• PiergaJYDelalogeSEspiéMA multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patientsBreast Cancer Res Treat20101222 42943720480225
   PubMed Web of Science ®Google Scholar
• GiacchettiSHamyASDelalogeSLong-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 statusEur J Cancer20177532333228279941
   PubMed Web of Science ®Google Scholar
• SubbaramaiahKHoweLRPortERHER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanismCancer Res20066610 5504551116707480
   PubMed Web of Science ®Google Scholar
• BenoitVRelicBLeval XdXChariotAMervilleMPBoursVRegulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2Oncogene2004238 1631163514985703
   PubMed Web of Science ®Google Scholar
• DangCTDannenbergAJSubbaramaiahKPhase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatmentsClin Cancer Res20041012 Pt 1 4062406715217939
   PubMed Web of Science ®Google Scholar
• El-AwadyRASalehEMEzzMElsayedAMInteraction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cellsToxicol Appl Pharmacol20112553 27128621763710
   PubMed Web of Science ®Google Scholar
• GatesMATworogerSSEliassenAHMissmerSAHankinsonSEAnalgesic use and sex steroid hormone concentrations in postmenopausal womenCancer Epidemiol Biomarkers Prev2010194 1033104120332258
   PubMed Web of Science ®Google Scholar
• MarshallSFBernsteinLAnton-CulverHNonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor statusJ Natl Cancer Inst20059711 80581215928301
   PubMedGoogle Scholar
• BrueggemeierRWDíaz-CruzESLiPKSugimotoYLinYCShapiroCLTranslational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancerJ Steroid Biochem Mol Biol2005951–5 12913615964185
   PubMed Web of Science ®Google Scholar
• SunXLvMWangBComparative pharmacokinetics study of anastrozole after single administration and combination with celecoxibXenobiotica2018483 1628010169
   PubMed Web of Science ®Google Scholar
• ChowLWChengCWWongJLToiMSerum lipid profiles in patients receiving endocrine treatment for breast cancer--the results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) TrialBiomed Pharmacother200559Suppl 2 S302S30516507398
   PubMedGoogle Scholar
• ChowLWYipAYLooWTLamCKToiMCelecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancerJ Steroid Biochem Mol Biol20081111–2 131718514508
   PubMed Web of Science ®Google Scholar
• CanneyPAMachinMACurtoJA feasibility study of the efficacy and tolerability of the combination of Exemestane with the COX-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancerEur J Cancer20064216 2751275617027257
   PubMed Web of Science ®Google Scholar
• FalandryCDebledMBachelotTCelecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO studyBreast Cancer Res Treat20091163 50150819020973
   PubMed Web of Science ®Google Scholar
• LustbergMBPovoskiSPZhaoWPhase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancerClin Breast Cancer2011114 22122721729671
   PubMed Web of Science ®Google Scholar
• DirixLYIgnacioJNagSTreatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxibJ Clin Oncol2008268 1253125918323548
   PubMed Web of Science ®Google Scholar
• BonebergEMLeglerDFSennHJFürstenbergerGReduced expression of cyclooxygenase-2 in primary breast cancerJ Natl Cancer Inst200810014 1042104318612134
   PubMedGoogle Scholar
• AristarcoVSerranoDGandiniSA Randomized, Placebo-Controlled, Phase II, Presurgical Biomarker Trial of Celecoxib Versus Exemestane in Postmenopausal Breast Cancer PatientsCancer Prev Res201695 349356
   PubMed Web of Science ®Google Scholar
• BasuGDTinderTLBradleyJMCyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDOJ Immunol20061774 2391240216888001
   PubMed Web of Science ®Google Scholar
• LiYFangMZhangJHydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunityOncoimmunology201652 e107437427057439
   PubMed Web of Science ®Google Scholar
• ChoHYThomasSGoldenEBEnhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stressCancer Lett20092821 879719345476
   PubMed Web of Science ®Google Scholar
• ThomasSSharmaNGoldenEBPreferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitorsCancer Lett20123251 637122664238
   PubMed Web of Science ®Google Scholar
• das RoyLPathangeyLBTinderTLSchettiniJLGruberHEMukherjeePBreast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritisBreast Cancer Res2009114 R5619643025
   PubMed Web of Science ®Google Scholar
• MustafaAKrugerWDSuppression of tumor formation by a cyclo-oxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancerClin Cancer Res20081415 4935494218676768
   PubMed Web of Science ®Google Scholar
• NiuGLiaoZCaiLWeiRSunLThe combined effects of celecoxib and minocycline hydrochloride on inhibiting the osseous metastasis of breast cancer in nude miceCancer Biother Radiopharm2008234 46947618771351
   PubMed Web of Science ®Google Scholar
• YuPLiuQLiuKYagasakiKWuEZhangGMatrine suppresses breast cancer cell proliferation and invasion via VEGF-Akt-NF-kappaB signalingCytotechnology2009593 21922919760125
   PubMed Web of Science ®Google Scholar
• WangSLiuQZhangYSuppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of actionMol Cancer200988119796390
   PubMed Web of Science ®Google Scholar
• JeonYWAhnYEChungWSChoiHJSuhYJSynergistic effect between celecoxib and luteolin is dependent on estrogen receptor in human breast cancer cellsTumour Biol2015368 6349635925851346
   PubMedGoogle Scholar
• JeonYWSuhYJSynergistic apoptotic effect of celecoxib and luteolin on breast cancer cellsOncol Rep2013292 81982523229294
   PubMed Web of Science ®Google Scholar
• KiskováTJendželovskýRRentsenEResveratrol enhances the chemopreventive effect of celecoxib in chemically induced breast cancer in ratsEur J Cancer Prev2014236 50651325254309
   PubMed Web of Science ®Google Scholar
• KimYJeYVitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysisBr J Cancer201411011 2772278424714744
   PubMed Web of Science ®Google Scholar
• RoseAAElserCEnnisMGoodwinPJBlood levels of vitamin D and early stage breast cancer prognosis: a systematic review and meta-analysisBreast Cancer Res Treat20131413 33133924104883
   PubMed Web of Science ®Google Scholar
• ThillMReichertKWoesteACombined treatment of breast cancer cell lines with vitamin D and COX-2 inhibitorsAnticancer Res2015352 1189119525667510
   PubMed Web of Science ®Google Scholar
• ThillMTerjungAFriedrichMBreast cancer--new aspects of tumor biology: are calcitriol and cyclooxygenase-2 possible targets for breast cancer?Eur J Gynaecol Oncol2014354 34135825118473
   PubMed Web of Science ®Google Scholar
• HowesLGSelective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice?Ther Clin Risk Manag200735 83184518473007
   PubMedGoogle Scholar
• AbassiYAXiBZhangWKinetic cell-based morphological screening: prediction of mechanism of compound action and off-target effectsChem Biol2009167 71272319635408
   PubMed Web of Science ®Google Scholar
• PyrkoPKardoshALiuYTCalcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxibMol Cancer Ther200764 1262127517431104
   PubMed Web of Science ®Google Scholar
• O’ConnorJPLyszTNSAIDs and the skeletonDrugs Today2008449 69370919137124
   PubMed Web of Science ®Google Scholar
• LeeJHParkHKHeoJDrug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome induced by celecoxib and anti-tuberculosis drugsJ Korean Med Sci2008233 52152518583892
   PubMed Web of Science ®Google Scholar
• ChenJShenPZhangXCZhaoMDZhangXGYangLEfficacy and safety profile of celecoxib for treating advanced cancers: a meta-analysis of 11 randomized clinical trialsClin Ther2014368 1253126325016505
   PubMed Web of Science ®Google Scholar
• MegeffCEStrayerSMCelecoxib for rheumatoid arthritisJ Fam Pract2000492 10810910718683
   PubMedGoogle Scholar